Elotuzumab as a novel anti-myeloma immunotherapy. Hum Vaccin Immunother 2017 Aug 03;13(8):1751-1757
Date
06/13/2017Pubmed ID
28604269Pubmed Central ID
PMC5557243DOI
10.1080/21645515.2017.1327487Scopus ID
2-s2.0-85020548304 (requires institutional sign-in at Scopus site) 4 CitationsAbstract
Treatment of multiple myeloma has undergone significant change in the last decade with the introduction of new immunomodulatory agents, proteasome inhibitors, and immunotherapeutic approaches. Elotuzumab is a humanized monoclonal antibody targeting CS1, which is a member of the SLAM (Signaling Lymphocyte Activation Molecule) family of proteins, expressed on the surface of myeloma plasma cells. Here we review the preclinical investigations that led to the development of elotuzumab and the clinical studies that resulted in its approval for the treatment of relapsed/refractory multiple myeloma. Although preclinical data looked very promising, elotuzumab monotherapy did not result in objective clinical responses in patients with relapsed/refractory multiple myeloma. However, combination treatment with immunomodulators and proteasome inhibitors resulted in substantial clinical activity in relapsed/refractory MM. Currently, there are several clinical trials ongoing investigating the role of elotuzumab in newly diagnosed myeloma patients and in patients receiving maintenance therapy.
Author List
Radhakrishnan SV, Bhardwaj N, Steinbach M, Weidner J, Luetkens T, Atanackovic DAuthor
Sabarinath Venniyil Radhakrishnan MD Assistant Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsAntibodies, Monoclonal, Humanized
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Clinical Trials as Topic
Humans
Immunologic Factors
Immunotherapy
Mice
Multiple Myeloma
Proteasome Inhibitors
Signaling Lymphocytic Activation Molecule Family
